
Anika Therapeutics (ANIK) Stock Forecast & Price Target
Anika Therapeutics (ANIK) Analyst Ratings
Bulls say
Anika Therapeutics Inc. reported a 21% growth in its international osteoarthritis (OA) pain revenue compared to the same quarter last year, driven by favorable order timing, and anticipates a positive cash position projected to reach around $60 million within the next 12 months. The company's regenerative solutions business also demonstrated robust performance with a 25% growth in the latest quarter, propelled by new product developments for the Integrity patch, which are expected to enhance its market presence and fuel continued growth. Additionally, Anika's fourth-quarter financial results surpassed expectations, showcasing a free cash flow of $5.0 million and indicating a strong trajectory towards significantly increased procedures and revenue in the upcoming years.
Bears say
Anika Therapeutics Inc reported a revenue decline of 5.9% year-over-year, generating $27.8 million, which fell short of revenue expectations despite outperforming adjusted EPS and cash generation metrics. The company's gross margin was disappointing at 56%, lower than the 58% estimate, partly due to ongoing production yield issues and persistent price headwinds within the U.S. market, which negatively impact profitability. Additionally, management's financial guidance indicates a contrasting outlook with anticipated 12-18% revenue growth in the commercial channel but a significant projected decline of 16-20% in the OEM channel, compounding the negative outlook given the failure of its pivotal FastTrack trial for Hyalofast, which did not meet its primary endpoints.
This aggregate rating is based on analysts' research of Anika Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Anika Therapeutics (ANIK) Analyst Forecast & Price Prediction
Start investing in Anika Therapeutics (ANIK)
Order type
Buy in
Order amount
Est. shares
0 shares